TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

Original reporting
Published Nov 7, 2026, 11:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransMedics revenue up 41% to USD 203M in Q3 2026 — source image
Decision brief

The 30-second read

Med
01

Why it matters

Revenue beat and record case volume suggest strong demand for the company's logistics platform, supporting a potential price rally. Margin compression and lower net income warrant monitoring.

02

Market read

Earnings release provides fresh data for traders; the 41% revenue jump is material and may drive short‑term price movement.

03

What to watch

Future revenue from ENHANCE Heart Part B and DENOVO Lung not yet realized; growth may be delayed.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

TransMedics Group, Inc. (NASDAQ: TMED) provides organ preservation and transport solutions. The Q3 2026 results were released on Nov 7, 2026.

Market effects

Positive signal for organ‑transplant logistics and medical device sector, may lift peers.

U.S. biotech/medical device market may see modest buying pressure.

Limited to healthcare investors; no broad market impact.

Counterpoint

Net income decline and higher operating expenses could signal margin pressure; caution on upside.

Key entities

  • TransMedics Group, Inc.

    Medical device company reporting Q3 2026 results.

Related articles

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.